Parkinson’s Disease (PD) is the second most common neurodegenerative disorder, affecting about 2% of people over 70. With an aging population, its prevalence is expected to triple in the coming years. Despite extensive research, there is still no treatment that can slow or stop the disease’s progression.
The Culprit: Alpha-Synuclein and Mitochondrial Dysfunction
At the heart of PD lies a protein called alpha-synuclein, which clumps together in neurons to form Lewy bodies—a hallmark of the disease. These protein aggregates are toxic to mitochondria, the energy-producing structures in cells. The resulting oxidative stress, neuroinflammation, and cell death contribute to the symptoms of PD.
Mitochondria are especially important in the brain, which consumes up to 25% of the body’s energy. When mitochondrial function is impaired, neurons—particularly those in the substantia nigra—become vulnerable and die off, leading to the motor symptoms of PD.
Genetic Links to Mitochondrial Dysfunction
Several genes associated with hereditary PD, such as SNCA, Parkin, PINK1, DJ-1, and LRRK2, are directly involved in mitochondrial health. Mutations in these genes can disrupt energy production, impair the removal of damaged mitochondria (mitophagy), and increase oxidative stress.
Metabolic Risk Factors
Emerging research suggests that metabolic health may influence PD risk. Obesity, insulin resistance, and type 2 diabetes have all been linked—though inconsistently—to increased PD risk. These conditions may worsen mitochondrial function, further contributing to neurodegeneration.
The Promise of Intermittent Fasting
Given the central role of mitochondria in PD, intermittent fasting (IF) has gained attention as a potential therapeutic strategy. IF may enhance mitochondrial function, reduce oxidative stress, and improve cellular resilience. The article proposes that targeting mitochondrial health through dietary interventions like IF could offer a new path forward in PD treatment.